Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
Findings from the randomised phase III study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
A Single Ciltacabtagene Autoleucel Infusion Results in a Lower Risk of Disease Progression or Death in Patients with Lenalidomide-Refractory Multiple Myeloma
Findings from the CARTITUDE-4 study
Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases Toxicity in Patients with RCC and Disease Progression on or After Previous ICI Treatment
Findings from the CONTACT-03 study
Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and Previously Treated Patients with BRAFV600-mutated Metastatic NSCLC
Findings from the PHAROS study
EMA Recommends Extension of Indications for Nivolumab
New indication concerns a combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence
Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in Patients with Treatment-Refractory, HER2-positive Biliary Tract Cancer
Findings from the pivotal HERIZON-BTC-01 study
Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line Treatment for Patients with mCRPC
Findings from the TALAPRO-2 study
FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated Metastatic Castration-Resistant Prostate Cancer
Evidence for efficacy is based on the results from the PROpel study
Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative Primary Operable Early Breast Cancer
Findings from the the window-of-opportunity TOT-HER3 study
Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with HR-positive, HER2-negative ABC Whose Disease Had Progressed to Previous AI With or Without a CDK4/6 Inhibitor
Findings from the CAPItello-291 study
EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F)
The benefit of this diagnostic radiopharmaceutical is its potential to diagnose prostate cancer during primary staging of patients at high risk and in the staging of patients with a suspected recurrence
Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed Patients with Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Findings from the prespecified final overall survival analysis of the PAOLA-1/ENGOT-ov25 study